Tmunity Therapeutics, a Philadelphia, PA-based company that is developing novel products that free the immunological potential of T cells to treat a wide range of disease indications, raised $10M in equity financing.
Backers included Penn Medicine, the academic medical center of the University of Pennsylvania (Penn), and Lilly Asia Ventures.
The company intends to use the funds to develop novel products.
Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors.
Tmunity was co-founded by Anne Chew, PhD, Executive Deputy Director of Penn’s Center for Cellular Immunotherapies, Carl H. June, MD, Richard W. Vague Professor of Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of Translational Research in Penn’s Abramson Cancer Center, Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy in the department of Pathology and Laboratory Medicine, Penn’s Abramson Cancer Center, and director of Penn’s Clinical Cell and Vaccine Production Facility, James L. Riley, PhD, associate professor of Microbiology and member of the Center for Cellular Immunotherapies at Penn’s Perelman School of Medicine, Yangbing Zhao, MD, PhD, director of the T-Cell Engineering Laboratory at the Center for Cellular Immunotherapies and Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine at Penn’s Perelman School of Medicine, and Bruce Blazar, MD, Regent’s Professor of Pediatrics, Director of the Clinical and Translational Science Institute as well as the Center for Translational Medicine, and Children’s Cancer Research Fund Land Grant Chair in Pediatric Oncology at the University of Minnesota.